News
$50 Million Gift from the Weill Family Foundation Establishes the Weill Cancer Hub East
March 2025
Collaborative Entity Formed by Princeton University, The Rockefeller University, Weill Cornell Medicine and the Ludwig Institute for Cancer Research to Investigate the Interplay Between Nutrition, Metabolism and Immunotherapy
TigaTx Announces up to $35.5M in Funding from ARPA-H and NIH Awards to Advance First-in-Class Engineered IgA Monoclonal Antibody for Cancer...
December 2024
TigaTx, Inc., a biotechnology company developing a therapeutic platform technology of engineered Immunoglobulin A (IgA) monoclonal antibodies to address a broad range of diseases, announced today that the Advanced Research Projects Agency for Health (ARPA-H) has awarded TigaTx up to $33.5 million in funding. Separately, TigaTx was awarded a two-year, $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the U.S. National Institutes of Health under award number R44CA291266.
Long-term Metastatic Melanoma Survival Dramatically Improves on Immunotherapy
September 2024
Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Institute investigators and their colleagues.
Drug-induced sugar high boosts T cell efficacy in immunotherapy
September 2024
Researchers led by Jedd Wolchok and Taha Merghoub, co-directors of the Ludwig Collaborative Laboratory at Weill Cornell, Ludwig MSK alumnus Roberta Zappasodi and first-author Svena Verma reported in The Journal of Clinical Investigation in September that treatment with an LDH inhibitor decreases tumor cell glucose uptake and proliferation but has exactly the opposite effect on tumor-infiltrating T cells in mice.
Stand Up To Cancer Dream Team Collective Seeks to Transform Care of Gastroesophageal Cancer
March 2024
A collaboration between Dr. Jedd Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, and Dr. Yelena Janjigian, chief of the gastrointestinal oncology service at Memorial Sloan Kettering Cancer Center, is looking to transform the care of gastroesophageal cancer (GEC) patients with untreatable disease – earning the pair a grant from Stand Up To Cancer® (SU2C) as a part of the SU2C-Torrey Coast Foundation Gastroesophageal Cancer Dream Team Collective.
Parker Institute for Cancer Immunotherapy (PICI) Welcomes Weill Cornell Medicine to Cancer Research Consortium
December 2023
The Parker Institute for Cancer Immunotherapy (PICI) announced it has added Weill Cornell Medicine to its network of preeminent academic and medical research institutions at the forefront of the fight against cancer.
Dr. Taha Merghoub and Dr. Jedd Wolchok won an ASPIRE Award from the Mark Foundation for Cancer Research
November 2023
Dr. Taha Merghoub, deputy director of the Sandra and Edward Meyer Cancer Center and Dr. Jedd Wolchok, the Meyer Director of the Meyer Cancer Center and a professor of medicine, won an ASPIRE Award from the Mark Foundation for Cancer Research. The awards support research in adult and pediatric cancers that aims to answer key feasibility and proof-of-concept questions in an accelerated timeframe.
Dr. Jedd Wolchok elected to National Academy of Medicine
October 2023
Dr. Jedd D. Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, in partnership with NewYork-Presbyterian, have been elected to the National Academy of Medicine (NAM). One of the most prestigious honors in health and medicine, the academy recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
Surprise Finding Shows That Neutrophils Can Be Key Antitumor Weapons
March 2023
In the study, published March 30 in Cell, the researchers investigated how a T cell-based immunotherapy was able to destroy melanoma tumors even though many of the tumor cells lacked the markers or “antigens” targeted by the T cells. They found that the T cells, in attacking the tumors, activated a swarm of neutrophils—which in turn killed the tumor cells that the T cells couldn’t eliminate. The findings could lead to new immunotherapies that harness this unexpected but potent antitumor immune response.
Dr. Jedd Wolchok Elected to the American Association for Cancer Research Board of Directors
March 2023
Dr. Jedd D. Wolchok, the Meyer Director of the Meyer Cancer Center and a professor of medicine, has been elected a member of the American Association for Cancer Research's Board of Directors. The association’s mission is to prevent and cure cancer through research, education, communication, collaboration, funding and advocacy. The association is the first and largest cancer research organization dedicated to accelerating the conquest of cancer.
Dr. Wolchok was one of five individuals elected for the 2023-2026 terms, with the mandate to work toward the AACR's mission of curing cancer.
Dr. Jedd Wolchok and Dr. Taha Merghoub Appointed Meyer Director and Deputy Director of the Sandra and Edward Meyer Cancer Center
July 2022
Dr. Jedd Wolchok, an internationally acclaimed medical oncologist whose innovations in immunotherapy have revolutionized melanoma treatment, has been recruited as the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, effective Sept. 12.
The institution has also appointed Dr. Taha Merghoub, a highly accomplished and innovative research scientist who has been Dr. Wolchok’s scientific partner at Memorial Sloan Kettering for over 15 years as well as a professor of immunology research in medicine at Weill Cornell Medicine, as deputy director of the Meyer Cancer Center.